BioNTech SE

Every October, Breast Cancer Awareness Month brings renewed attention to breast cancer, the progress made through research and the challenges that remain. But it is also a moment to make sure that all individuals living with breast cancer are part of the conversation – including those for whom the path looks very different. Read more:

𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗡𝗲𝘄𝘀: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝗲𝘄 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝗴𝘆𝗻𝗲𝗰𝗼𝗹𝗼𝗴𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 At the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer (#SGOAM26) we will share new data from two of our antibody-drug conjugate (ADC) programs in endometrial, cervical, and ovarian cancer. At #BioNTech we are advancing the development of innovative ADC treatment approaches across multiple tumor types, as we believe that these approaches may have potential to further transform cancer care – whether as monotherapies or as part of innovative, potentially synergistic combination approaches with other therapies. 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: • Gynecologic cancers affect more than 𝟭.𝟯 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝘄𝗼𝗺𝗲𝗻 𝗴𝗹𝗼𝗯𝗮𝗹𝗹𝘆 each year. • Endometrial cancer is the 𝟰𝘁𝗵 𝗺𝗼𝘀𝘁 𝗰𝗼𝗺𝗺𝗼𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗶𝗻 𝘄𝗼𝗺𝗲𝗻 with an 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴 𝗺𝗼𝗿𝘁𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝘁𝗲. • Ovarian cancer is the 𝟲𝘁𝗵 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗰𝗮𝘂𝘀𝗲 𝗼𝗳 𝗰𝗮𝗻𝗰𝗲𝗿-𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗱𝗲𝗮𝘁𝗵 𝗮𝗺𝗼𝗻𝗴 𝘄𝗼𝗺𝗲𝗻. • 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝘁𝗶𝗼𝗻𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝗹𝗶𝗺𝗶𝘁𝗲𝗱, especially for women with advanced or recurrent disease. We are committed to contributing to the future of women's health. 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗣𝗿𝗲𝘀𝘀 𝗥𝗲𝗹𝗲𝗮𝘀𝗲 𝗵𝗲𝗿𝗲: https://lnkd.in/ddKyZMYN #WomensCancer #WomensHealth #GynecologicOncology #CancerResearch

At #BioNTech, every day is World Cancer Day. 🎗 The voices from our colleagues shared this week reflect what drives our work every day. It’s our passion to translate science into survival. #WorldCancerDay

🎗𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 𝐞𝐧𝐝𝐬 𝐰𝐢𝐭𝐡 𝐚 𝐬𝐢𝐦𝐩𝐥𝐞 𝐫𝐞𝐦𝐢𝐧𝐝𝐞𝐫 𝐭𝐡𝐚𝐭 𝐞𝐯𝐞𝐫𝐲 𝐦𝐢𝐧𝐮𝐭𝐞 𝐜𝐨𝐮𝐧𝐭𝐬. Lung cancer remains the most common cancer worldwide. 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰? 🫁 𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐨𝐟𝐭𝐞𝐧 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐬 𝐬𝐢𝐥𝐞𝐧𝐭𝐥𝐲 Early symptoms can be mild or go unnoticed, which is why many cases are diagnosed at advanced stages. 🧬 𝐋𝐮𝐧𝐠 𝐜𝐚𝐧𝐜𝐞𝐫 𝐢𝐬 𝐧𝐨𝐭 𝐨𝐧𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 NSCLC accounts for about 87% of cases and SCLC about 13%. Both are biologically complex and often require new scientific approaches. 🔬 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐦𝐚𝐝𝐞 𝐛𝐮𝐭 𝐮𝐧𝐦𝐞𝐭 𝐧𝐞𝐞𝐝𝐬 𝐫𝐞𝐦𝐚𝐢𝐧 Significant progress has been made in treating certain sub-types of lung cancer, but there remains an urgent need for new treatment options that offer more durable outcomes. Our ultimate goal is to translate science into meaningful survival benefits for many patients by addressing some of the biggest challenges in cancer treatment. Our investigational therapies in lung cancer span mRNA cancer immunotherapies, immunomodulators, and targeted therapies in form of ADCs, aiming to support and activate the immune system in complementary ways. By deepening our understanding of how lung tumors interact with the immune system and which barriers limit effective responses, we aim to generate insights that may help guide future therapeutic approaches. Raising awareness is a start. Driving innovation is the goal, 𝐛𝐞𝐜𝐚𝐮𝐬𝐞 𝐞𝐯𝐞𝐫𝐲 𝐦𝐢𝐧𝐮𝐭𝐞 𝐜𝐨𝐮𝐧𝐭𝐬. #LungCancerAwarenessMonth #LungCancer #Oncology #CancerResearch #everyminutecounts

🔬 𝐁𝐢𝐨𝐍𝐓𝐞𝐜𝐡 𝐱 𝐄𝐒𝐌𝐎 𝟐𝟎𝟐𝟓 We at #BioNTech joined the global oncology community at ESMO 2025 in Berlin. From early-morning sessions to late-night discussions and countless insightful conversations in between, our teams were part of the scientific exchange. Guided by our mission: Translating science into survival. We are advancing science with the aim of transforming how cancer is treated, based on our investigative therapeutic approaches across: ✔️mRNA cancer immunotherapies ✔️Next-generation immunomodulators ✔️Targeted therapies This year’s congress once again highlighted the importance of innovation, scientific excellence, and collaboration to help shape the next era of cancer medicine. 🎥 Thank you to our colleagues and partners on site and everyone who visited our booth. Together we moved one step further in our shared goal to help improve outcomes for people living with cancer. #ESMO25 #Oncology #CancerResearch #Science #Biotech